AWM
BBIO icon

Abound Wealth Management’s BridgeBio Pharma BBIO Stock Holding History

Abound Wealth Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149 Buy
+2
New +$140 ﹤0.01% 1187

Other funds holding BBIO

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
FBT
First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $984M AUM 34.19% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Abound Wealth Management's BBIO Position: Q2 2026 in Review

Abound Wealth Management opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 2 shares worth $149. The stake represents ﹤0.01% of the portfolio and ranks #1187 among its holdings.

40 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Abound Wealth Management held 2 shares of BridgeBio Pharma worth $149 as of Q2 2026.
  • BridgeBio Pharma was a new Abound Wealth Management position in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #1187 holding.
  • 40 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.